Research Project

Project Title:	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Project Type:	Clinical Trial, Enrolment ongoing Adjunct biobank: Serum, Plasma, Urine
Disease group(s):	Immune glomerulopathies
Project Summary:	To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
Lead principal investigator(s):	William Morello, Milan
Project Period:	09/2018 - 09/2050
Sponsors:	Industry
Project web page:	https://www.orpha.net/en/research-trials/clinical-trial/659051?name=&mode=&country=&recruiting=0&terminated=0
EudraCT Nr.:	2016-00514123